Patients with type 2 diabetes who were treated with Anakinra, Interleukin-1 receptor antagonist (IL-1Ra), for 13 weeks had reduced HbA1c, reduced systemic IL-6, IL-17, and C-reactive peptide, and an increased secretion of C-peptide [114]. The gene discussed is IL6; the disease is type 2 diabetes mellitus.